Tech Transfer Roundup: Entrepreneurial Culture Matters
Believing biomedical research at Duke is “under fished” compared to the ponds in San Francisco and Boston, Duke’s institutional CRO looks to provide clinical trial design and other services to help tech transfer along. Plus, recent tech transfer deals include AbbVie, Calimmune and China’s Yisheng.
You may also be interested in...
Emerging Company Profile: With mononuclear stem cell therapy from University of Texas research, new company hopes to address traumatic brain injury by reducing the pro-inflammatory cytokine cascade, which exacerbates the initial injuries in severe TBI.
Japan has formally enacted new legislation governing the development, approval and use of regenerative medicines, including induced pluripotent stem (iPS) cells, in a move welcomed by companies both inside and outside the country.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.